This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grabar, S. Articles by Costagliola, D. Search for Related Content PubMed PubMed Citation Articles by Grabar, S. Articles by Costagliola, D. Pubmed/NCBI databases Medline Plus Health Information Kaposi's Sarcoma Social Bookmarking                            What's this?

Differential Impact of Combination Antiretroviral Therapy in Preventing Kaposi's Sarcoma With and Without Visceral Involvement

Sophie Grabar, Bruno Abraham, Aba Mahamat, Pascal Del Giudice, Eric Rosenthal, Dominique Costagliola

From the Service de Biostatistique et Informatique Médicale, Hôpital Cochin, Université René Descartes; Institut National de la Santé Et de la Recherche Médical, Unité Mixte de Recherche 720, Université Pierre et Marie Curie, Paris; Service de Médecine interne, Hôpital de Brive-la-Gaillarde, Brive-la-Gaillarde; Service de Médecine interne, Carémeau University Hospital, Nîmes; Service de Dermatologie, Hôpital de Fréjus, Fréjus; and the Service de Médecine Interne-Cancérologie, Hôpital l'Archet, Nice, France

Address reprint requests to Sophie Grabar, MD, PhD, Hôpital Cochin, Service de Biostatistique et Informatique Médicale, 27 Rue du Fg St Jacques, 75 679 Paris CEDEX 14, France; e-mail: sophie.grabar{at}univ-paris5.fr

PURPOSE: To study the impact of different potent combined antiretroviral treatment (cART) on the incidence of HIV-associated Kaposi's sarcoma (KS) with and without visceral involvement.

PATIENTS AND METHODS: Patients were selected from the French Hospital Database on HIV, a large hospital cohort. The risk of KS was estimated by using Cox proportional hazards models adjusting for age, the CD4 cell nadir, the HIV exposure category, prior AIDS, cART, and the type of cART regimen. cART regimens were distinguished according to whether they contained protease inhibitor (PI), non-nucleoside analog (NNRTI), both, or only nucleoside analog (NRTI). Separate analyzes were conducted according to the initial visceral involvement of KS.

RESULTS: Among the 54,999 patients included in this study (182,756 person-years of follow-up), 1,634 patients were diagnosed with KS during follow-up, of whom 421 had visceral involvement at diagnosis. The KS incidence rate fell from 32 per 1,000 person-years in 1993 to 1994 to 3 per 1,000 person-years after 1999. PI-containing and NNRTI-containing cART regimens were associated with similar reductions in the risk of KS (hazard ratio, 0.68; 95%CI, 0.61 to 0.75; HR, 0.62; 95% CI, 0.54 to 0.71, respectively). The risk of visceral KS fell more strongly than the risk of cutaneous KS (> 50% and < 30%, respectively).

CONCLUSION: The incidence of KS, and especially visceral KS, has fallen sharply since the advent of cART. This effect is likely due to immune restoration rather than to a specific effect on the tumoral process, as PI-containing and NNRTI-containing regimens had similar preventive efficacy.

Supported by Agence Nationale de Recherches sur le SIDA (French Hospital Database on HIV), Fondation pour la Recherche Médicale, Institut National de la Santé et de la Recherche Médicale, and the French Ministry of Health.

Presented in part at the 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 22-25, 2005.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J.-P. Spano, D. Costagliola, C. Katlama, N. Mounier, E. Oksenhendler, and D. Khayat AIDS-Related Malignancies: State of the Art and Therapeutic Challenges J. Clin. Oncol., October 10, 2008; 26(29): 4834 - 4842. [Abstract] [Full Text] [PDF]